Madhusudan V. Peshwa PhD

Dr. Madhusudan V. Peshwa, Ph.D serves as an Executive Vice President of Cellular Therapies of MaxCyte, Inc. Dr. Peshwa served as a Vice President of Research and Development of MaxCyte, Inc. since March 2005. Prior to joining MaxCyte, Dr. Peshwa served as an Executive Vice President, Research and Development at NewNeural LLC. Previously, he served as a Vice President, Manufacturing and as a Vice President, Process Sciences at Dendreon Corporation, where he was responsible for the development, characterization, and manufacture of an autologous dendritic cell vaccine product (“Provenge”) from concept to late Phase III pivotal studies. He is a Member of Global Advisory Board of Epidarex Capital. He is a Co-author on over 35 scientific publications and is a Co-inventor on five, issued or under review, patent applications. His expertise is in the areas of design, characterization, scale-up, and implementation of processes, and cGMP systems in the development of engineered cell and tissue products and for biopharmaceuticals’ production. Dr. Peshwa holds a Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in Chemical Engineering from the Indian Institute of Technology, Kanpur, India.

Madhusudan V. Peshwa, Ph.D., currently serves as Executive Vice President, Cellular Therapies at MaxCyte, Inc., a clinical stage biotechnology company with a platform technology for accelerating development of small molecule drugs and biologics and enabling clinical development of enhanced’ potency cellular therapies for treatment of immune diseases and regenerative medicine applications. Prior to joining MaxCyte in 2005 as Vice President, Research and Development, Dr. Peshwa participated in the capacity as Limited Partner and Executive Vice President, Research & Development at New Neural LLC, , a company developing pharmaceutical drugs and stem cell therapies for treatment of CNS diseases. Previously, he served as Vice President of Manufacturing and as Vice President of Process Sciences at Dendreon Corporation (NASDAQ: DNDN). During his 10 year tenure with Dendreon, Dr. Peshwa participated in the PMA approval of a stem cell isolation device and was responsible for the development, characterization and manufacture of an active immunotherapy product, PROVENGE (sipuleucel-T) – approved by U.S. FDA for treatment of prostate cancer, from concept to completion of Phase III studies. Prior to joining Dendreon, Dr. Peshwa was involved in initiating operations through IND filing for Regenerex Inc., a University of Minnesota spinout focused on development of a bio-artificial liver as an extracorporeal device for treatment of acute fulminant hepatitis, a technology developed as part of Dr. Peshwa’s doctoral dissertation work.

Dr. Peshwa obtained his Ph.D. in Chemical Engineering from the University of Minnesota and his B.Tech. in Chemical Engineering from the Indian Institute of Technology, Kanpur, India. He is a co-author on 40 scientific publications and is a co-inventor on 8 issued or under review patents and patent applications. Dr. Peshwa has served as Principal-/Co- Investigator on multiple funded grant applications; Guest Editor for the journal Biotechnology and Bioengineering; Associate Editor for the journal Cytotechnology; and has served on multiple Advisory Boards at academic/research institutes, life science companies, venture capital, and no-for-profit professional organization.